Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85

ConclusionsOur data suggest that miR-503 might be a sensitizer to cisplatin treatment in ovarian cancer by targeting PI3K p85, thus giving a new insight into developing therapeutic strategies to overcome cisplatin resistance in ovarian cancer.

http://link.springer.com/10.1007/s00404-018-4649-0

Source: Archives of Gynecology and Obstetrics - January 11, 2018 Category: OBGYN Source Type: research